Common Stock, Shares, Issued of Outlook Therapeutics, Inc. from 30 Sep 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
Outlook Therapeutics, Inc. quarterly Common Stock, Shares, Issued in shares history and change rate from 30 Sep 2015 to 31 Dec 2025.
  • Outlook Therapeutics, Inc. Common Stock, Shares, Issued for the quarter ending 31 Dec 2025 was 64,556,570, a 159% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Change (%)

Outlook Therapeutics, Inc. Quarterly Common Stock, Shares, Issued (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 64,556,570 +39,650,935 +159% 31 Dec 2025 10-Q 17 Feb 2026 2026 Q1
Q3 2025 53,887,233 +29,981,598 +125% 30 Sep 2025 10-Q 17 Feb 2026 2026 Q1
Q2 2025 43,479,051 +20,073,414 +86% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q3
Q1 2025 32,907,014 +10,894,187 +49% 31 Mar 2025 10-Q 15 May 2025 2025 Q2
Q4 2024 24,905,635 -235,351,882 -90% 31 Dec 2024 10-Q 14 Feb 2025 2025 Q1
Q3 2024 23,905,635 +10,892,802 +84% 30 Sep 2024 10-K 19 Dec 2025 2025 FY
Q2 2024 23,405,637 -235,298,418 -91% 30 Jun 2024 10-Q 14 Aug 2024 2024 Q3
Q1 2024 22,012,827 -234,653,967 -91% 31 Mar 2024 10-Q 15 May 2024 2024 Q2
Q4 2023 260,257,517 +3,590,723 +1.4% 31 Dec 2023 10-Q 14 Feb 2024 2024 Q1
Q3 2023 13,012,833 -214,297,739 -94% 30 Sep 2023 10-K 27 Dec 2024 2024 FY
Q2 2023 258,704,055 +32,761,336 +14% 30 Jun 2023 10-Q 14 Aug 2023 2023 Q3
Q1 2023 256,666,794 +30,874,052 +14% 31 Mar 2023 10-Q 15 May 2023 2023 Q2
Q4 2022 256,666,794 +32,406,192 +14% 31 Dec 2022 10-Q 14 Feb 2023 2023 Q1
Q3 2022 227,310,572 +50,848,944 +29% 30 Sep 2022 10-K 22 Dec 2023 2023 FY
Q2 2022 225,942,719 +51,129,393 +29% 30 Jun 2022 10-Q 10 Aug 2022 2022 Q3
Q1 2022 225,792,742 +52,186,935 +30% 31 Mar 2022 10-Q 13 May 2022 2022 Q2
Q4 2021 224,260,602 +97,077,493 +76% 31 Dec 2021 10-Q 14 Feb 2022 2022 Q1
Q3 2021 176,461,628 +49,278,519 +39% 30 Sep 2021 10-K 29 Dec 2022 2022 FY
Q2 2021 174,813,326 +48,453,262 +38% 30 Jun 2021 10-Q 13 Aug 2021 2021 Q3
Q1 2021 173,605,807 +83,854,615 +93% 31 Mar 2021 10-Q 14 May 2021 2021 Q2
Q4 2020 127,183,109 +88,752,185 +231% 31 Dec 2020 10-Q 16 Feb 2021 2021 Q1
Q3 2020 127,183,109 +98,573,114 +345% 30 Sep 2020 10-K 23 Dec 2021 2021 FY
Q2 2020 126,360,064 +98,127,036 +348% 30 Jun 2020 10-Q 14 Aug 2020 2020 Q3
Q1 2020 89,751,192 +77,991,562 +663% 31 Mar 2020 10-Q 15 May 2020 2020 Q2
Q4 2019 38,430,924 -46,660,862 -55% 31 Dec 2019 10-Q 14 Feb 2020 2020 Q1
Q3 2019 28,609,995 +19,582,504 +217% 30 Sep 2019 10-K 23 Dec 2020 2020 FY
Q2 2019 28,233,028 -43,965,440 -61% 30 Jun 2019 10-Q 14 Aug 2019 2019 Q3
Q1 2019 11,759,630 -13,980,828 -54% 31 Mar 2019 10-Q 15 May 2019 2019 Q2
Q4 2018 85,091,786 +59,561,059 +233% 31 Dec 2018 10-Q 14 Feb 2019 2019 Q1
Q3 2018 9,027,491 -15,906,453 -64% 30 Sep 2018 10-K 19 Dec 2019 2019 FY
Q2 2018 72,198,468 +47,539,416 +193% 30 Jun 2018 10-Q 14 Aug 2018 2018 Q3
Q1 2018 25,740,458 +1,640,507 +6.8% 31 Mar 2018 10-Q 15 May 2018 2018 Q2
Q4 2017 25,530,727 +1,942,696 +8.2% 31 Dec 2017 10-Q 14 Feb 2018 2018 Q1
Q3 2017 24,933,944 +2,131,166 +9.3% 30 Sep 2017 10-K 18 Dec 2018 2018 FY
Q2 2017 24,659,052 +24,659,052 30 Jun 2017 10-Q 14 Aug 2017 2017 Q3
Q1 2017 24,099,951 +24,099,951 31 Mar 2017 10-Q 15 May 2017 2017 Q2
Q4 2016 23,588,031 31 Dec 2016 10-Q 14 Feb 2017 2017 Q1
Q3 2016 22,802,778 +13,366,484 +142% 30 Sep 2016 10-K 29 Dec 2017 2017 FY
Q2 2016 0 30 Jun 2016 10-Q 15 Aug 2016 2016 Q3
Q1 2016 0 31 Mar 2016 10-Q 27 Jun 2016 2016 Q2
Q3 2015 9,436,294 30 Sep 2015 10-K 29 Dec 2016 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.